- Posted April 08, 2014
- Tweet This | Share on Facebook
Supreme Court takes up drug company dispute
WASHINGTON (AP) -- The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed last week to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
A federal district court had earlier ruled in Teva's favor and upheld the patents. Teva says the federal circuit should have deferred to factual findings made in the district court.
The justices will hear the case in the fall.
Published: Tue, Apr 8, 2014
headlines Oakland County
- Historical: Circuit Court judge has made indelible mark
- ABA amicus brief supports noncitizens’ right to a bond hearing when detention becomes ‘unreasonably prolonged’
- Nessel secures full victory in lawsuit challenging administration’s attack on fair housing protections
- Whitmer announces new automotive jobs, investment in Oakland County
- AG pushes federal government to strengthen rules to combat illegal robocalls
headlines National
- ABA Legal Ed council repeals DEI standard
- Is Perry Mason TV’s most effective lawyer? New study names top 5
- Lawyer who cited paraphrasing as direct quotes in 2nd Circuit brief says AI played a role
- After jury deadlock and mistrial, Lindsay Clancy could face second trial
- Murder, Corruption and RICO in Georgia: Fateful meeting I didn’t want to attend led to courtroom win
- Bad Bunny, Justin Bieber among musical stars facing copyright suit for using reggaeton’s signature beat




